BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23708070)

  • 1. Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).
    Yazbeck VY; Villaruz L; Haley M; Socinski MA
    Cancer J; 2013; 19(3):231-7. PubMed ID: 23708070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Mehta V
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
    Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
    Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of dosimetric and clinical factors with the development of esophagitis and radiation pneumonitis in patients with limited-stage small-cell lung carcinoma.
    Giuliani ME; Lindsay PE; Kwan JY; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ
    Clin Lung Cancer; 2015 May; 16(3):216-20. PubMed ID: 25532963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol.
    Ninomiya K; Ichihara E; Hotta K; Sone N; Murakami T; Harada D; Oze I; Kubo T; Tanaka H; Kuyama S; Kishino D; Bessho A; Harita S; Katsui K; Tanimoto M; Kiura K
    Clin Lung Cancer; 2017 Mar; 18(2):245-249. PubMed ID: 27847247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    Mehmood Q; Sun A; Becker N; Higgins J; Marshall A; Le LW; Vines DC; McCloskey P; Ford V; Clarke K; Yap M; Bezjak A; Bissonnette JP
    J Thorac Oncol; 2016 Feb; 11(2):213-21. PubMed ID: 26718880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
    Dandekar VK; Young J; Kiel K; Bonomi P; Fidler MJ; Batus M; Sher DJ
    Am J Clin Oncol; 2015 Dec; 38(6):605-9. PubMed ID: 24781341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy.
    Yegya-Raman N; Reyhan M; Kim S; Deek MP; Yue N; Zou W; Malhotra J; Aisner J; Jabbour SK
    Pract Radiat Oncol; 2019 Jan; 9(1):e74-e82. PubMed ID: 30144583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience.
    Mantel F; Müller E; Kleine P; Zimmermann M; Exner F; Richter A; Weick S; Ströhle S; Polat B; Höcht S; Flentje M
    Strahlenther Onkol; 2021 May; 197(5):405-415. PubMed ID: 33725133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer.
    Kuroda Y; Sekine I; Sumi M; Sekii S; Takahashi K; Inaba K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Murakami N; Morota M; Mayahara H; Ito Y; Tamura T; Nemoto K; Itami J
    Technol Cancer Res Treat; 2013 Aug; 12(4):333-9. PubMed ID: 23369154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB non-small-cell lung cancer.
    Imamura F; Konishi K; Uchida J; Nishino K; Okuyama T; Kumagai T; Kawaguchi Y; Nishiyama K
    Clin Lung Cancer; 2014 Jul; 15(4):281-6. PubMed ID: 24656641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.
    Ma L; Qiu B; Li Q; Chen L; Wang B; Hu Y; Liu M; Zhang L; Huang Y; Deng X; Xia Y; Lin M; Liu H
    Radiat Oncol; 2018 Jul; 13(1):130. PubMed ID: 30016978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
    Antonadou D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
    Werner-Wasik M; Paulus R; Curran WJ; Byhardt R
    Clin Lung Cancer; 2011 Jul; 12(4):245-51. PubMed ID: 21726824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
    Komaki R; Lee JS; Kaplan B; Allen P; Kelly JF; Liao Z; Stevens CW; Fossella FV; Zinner R; Papadimitrakopoulou V; Khuri F; Glisson B; Pisters K; Kurie J; Herbst R; Milas L; Ro J; Thames HD; Hong WK; Cox JD
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):46-9. PubMed ID: 11917284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy.
    Komaki R; Chang JY; Wu X; Allen PK; Milas L; Liao Z; Fossella FV; Travis E; Spitz MR
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S92-8. PubMed ID: 16015542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer.
    Niho S; Kubota K; Nihei K; Sekine I; Sumi M; Sekiguchi R; Funai J; Enatsu S; Ohe Y; Tamura T
    Clin Lung Cancer; 2013 Jan; 14(1):62-9. PubMed ID: 22633219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.
    Palma DA; Senan S; Oberije C; Belderbos J; de Dios NR; Bradley JD; Barriger RB; Moreno-Jiménez M; Kim TH; Ramella S; Everitt S; Rengan R; Marks LB; De Ruyck K; Warner A; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):690-6. PubMed ID: 24035329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thoracic Radiation Normal Tissue Injury.
    Simone CB
    Semin Radiat Oncol; 2017 Oct; 27(4):370-377. PubMed ID: 28865520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.